Trial Profile
A Phase II Study of Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Adenoid cystic carcinoma
- Focus Therapeutic Use
- 26 Aug 2016 Results published in the Annals of Oncology
- 18 Aug 2016 Status changed from active, no longer recruiting to completed.
- 28 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017.